Page last updated: 2024-10-31

metyrapone and Hypertension, Malignant

metyrapone has been researched along with Hypertension, Malignant in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Hypertension, Malignant: A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
HOFFMEISTER, W1

Other Studies

1 other study available for metyrapone and Hypertension, Malignant

ArticleYear
[PATHOPHYSIOLOGY AND CLINICAL ASPECTS OF SECONDARY ALDOSTERONISM AND ITS TREATMENT].
    Folia clinica internacional, 1964, Volume: 14

    Topics: Adrenocorticotropic Hormone; Aldosterone; Ascites; Body Fluids; Classification; Dexamethasone; Extra

1964